Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02879695 |
| Title | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | National Cancer Institute (NCI) |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult | child |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Yale University | New Haven | Connecticut | 06520 | United States | Details | |
| University of Kentucky/Markey Cancer Center | Lexington | Kentucky | 40536 | United States | Details | |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21287 | United States | Details | |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | United States | Details | |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania | 15232 | United States | Details | |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | United States | Details |